| DC11019 |
ASP3662
Featured
|
ASP3662 is a potent, selective, CNS-penetrable and orally active inhibitor of 11β-HSD1 with Ki of 5.3, 2.6 and 23 nM for human, mouse and rat 11β-HSD1, does not inhibit human 11β-HSD2 at 30 uM. |
|
| DCS-019 |
(-)-Huperzine A |
>98%,Standard References |
|
| DCJ-030 |
Galanthamine |
>98%,Standard References |
|
| DC11301 |
ALZ-801
Featured
|
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. |
|
| DC9946 |
Lanabecestat(AZD3293,LY-3314814) |
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
|
| DC8400 |
AZD3839
Featured
|
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1. |
|
| DC8338 |
Azeliragon（PF-04494700,TTP488）
Featured
|
Azeliragon is an oral, small-molecule inhibitor of RAGE. |
|
| DC11105 |
Umibecestat
Featured
|
beta-secretase inhibitor. |
|
| DC11389 |
BI 409306
Featured
|
BI 409306 is an inhibitor of phosphodisterase 9A（PDE9A）. |
|
| DC3114 |
Avagacestat (BMS-708163)
Featured
|
BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively. |
|
| DC11038 |
Bryostatin 1
Featured
|
Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM). |
|
| DC10506 |
CPHPC(Miridesap)
Featured
|
CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance. |
|
| DC8277 |
E-2012
Featured
|
E 2012 is a potent γ-secretase modulator. |
|
| DC11551 |
Elenbecestat
Featured
|
Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease.. |
|
| DC10490 |
GIBH-130
Featured
|
GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models. |
|
| DC5061 |
GYKI 52466 dihydrochloride |
GYKI 52466 dihydrochloride is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. |
|
| DC9329 |
(±)-Huperzine A |
Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD). |
|
| DC5180 |
LY2811376
Featured
|
LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM. |
|
| DC5053 |
LY2886721
Featured
|
LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease. |
|
| DC5036 |
LY-411575
Featured
|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM. |
|
| DC9901 |
Verubecestat (MK-8931)
Featured
|
MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase. |
|
| DC11247 |
Nelonicline
Featured
|
Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia.. |
|
| DC11367 |
PF-04447943
Featured
|
PF-04447943 is a brain-permeable phosphodiesterase (PDE) inhibitor that is selective for PDE9A (IC50 = 12 nM) over other PDEs (IC50s = >940 nM) in enzymatic assays of second messenger hydrolysis. |
|
| DC9915 |
PF04995274,PF 04995274
Featured
|
PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD). |
|
| DCAPI1435 |
Rivastigmine tartrate |
Rivastigmine hydrogen tartrate is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and Parkinson's disease. |
|
| DC7496 |
Semagacestat
Featured
|
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM. |
|
| DC9842 |
T0901317
Featured
|
T0901317 is a potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-α and LXR-β respectively). |
|
| DC11208 |
TAK-071
Featured
|
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM. |
|
| DC10217 |
TRx0237 (LMTX) mesylate
Featured
|
TRx 0237 (LMTX™) mesylate is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. |
|
| DC4173 |
VX-745
Featured
|
VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively. |
|
